IVIG dose options for newly diagnosed childhood ITP
Treatments studied
Part of Blood & lymphatic clinical trials.
This study compares two intravenous (IV) IgG treatment regimens for children newly diagnosed with immune thrombocytopenia (ITP). It aims to find a regimen that works well and is safe for raising low platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been newly diagnosed with ITP and has never been treated for it
- Your child is older than 28 days and no older than 14 years
- Your child’s platelet count is very low (below 20 × 10^9/L)
- A parent or legal guardian signs the informed consent
- Your child has not had IVIG or steroid (glucocorticoid) treatment in the last 6 months
- Your child does not have certain serious bleeding problems or other major conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
This trial studies a short, high-dose steroid plan (prednisone plus dexamethasone) to treat immune thrombocytopenia (ITP) in children and raise low platelet counts. It may help reduce bleeding risk while using an approach tested in children soon after diagnosis.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
Hear when a new Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.